HomeCompareAMYT vs EQR

AMYT vs EQR: Dividend Comparison 2026

AMYT yields 13.61% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMYT wins by $1.1K in total portfolio value
10 years
AMYT
AMYT
● Live price
13.61%
Share price
$14.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.9K
Annual income
$3,165.25
Full AMYT calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — AMYT vs EQR

📍 AMYT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMYTEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMYT + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMYT pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMYT
Annual income on $10K today (after 15% tax)
$1,156.46/yr
After 10yr DRIP, annual income (after tax)
$2,690.46/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $1,963.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMYT + EQR for your $10,000?

AMYT: 50%EQR: 50%
100% EQR50/50100% AMYT
Portfolio after 10yr
$48.4K
Annual income
$4,320.43/yr
Blended yield
8.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AMYT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$14.50
-1.4% upside vs current
Range: $14.50 — $14.50
Altman Z
0.0
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMYT buys
0
EQR buys
0
No recent congressional trades found for AMYT or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMYTEQR
Forward yield13.61%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$48.9K$47.8K
Annual income after 10y$3,165.25$5,475.61
Total dividends collected$22.3K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$14.50$70.35

Year-by-year: AMYT vs EQR ($10,000, DRIP)

YearAMYT PortfolioAMYT Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$12,061$1,360.54$11,380$679.82+$681.00AMYT
2$14,438$1,533.54$13,014$837.25+$1.4KAMYT
3$17,165$1,715.78$14,961$1,036.20+$2.2KAMYT
4$20,273$1,906.34$17,297$1,289.22+$3.0KAMYT
5$23,796$2,104.21$20,121$1,613.15+$3.7KAMYT
6$27,770$2,308.32$23,561$2,030.84+$4.2KAMYT
7$32,231$2,517.59$27,783$2,573.54+$4.4KAMYT
8$37,219$2,730.91$33,013$3,284.39+$4.2KAMYT
9$42,771$2,947.15$39,547$4,223.51+$3.2KAMYT
10$48,930$3,165.25$47,791$5,475.61+$1.1KAMYT

AMYT vs EQR: Complete Analysis 2026

AMYTStock

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Full AMYT Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this AMYT vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMYT vs SCHDAMYT vs JEPIAMYT vs OAMYT vs KOAMYT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.